Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 30, 2015 5:52 AM ET

Life Sciences Tools and Services

Company Overview of EMD Millipore Corporation

Company Overview

EMD Millipore Corporation provides solutions and services for research, development, and production of biotechnology and pharmaceutical drug therapies. It offers bioscience products and services, such as antibodies and assays, protein detection and quantification, inhibitors and biochemicals, proteins and enzymes, cell culture and systems, genomic analysis, and cell analysis; lab solutions, such as chemical and reagents, IVD/OEM materials and reagents, microbiological testing and process monitoring, and related services; and process solutions, including sterile filtration, virus reduction, biopharma raw materials, drug delivery compounds, engineering, and validation services. The company als...

290 Concord Road

Billerica, MA 01821-7037

United States

Founded in 1954

6,100 Employees

Phone:

781-533-6000

Fax:

781-533-3110

Key Executives for EMD Millipore Corporation

Chief Executive Officer and President
Head of Finance and Controlling
Head of Global Operations and Member of Management Board
Age: 61
Member of Management Board and President of Emd Millipore Division
Member of Management Board and Head of Emd Millipore's Bioscience Business Unit
Age: 49
Compensation as of Fiscal Year 2015.

EMD Millipore Corporation Key Developments

EMD Millipore Adds Protein Pegylation to Portfolio of Services for Biopharmaceutical Industry through Collaboration with celares GmbH

EMD Millipore announced a collaboration with celares GmbH to provide pegylation services to customers developing protein-based therapeutics and biosimilars. The new service offering enabled by the collaboration includes feasibility studies, process and analytical development, and scale-up from milligram to gram quantities required for pilot and subsequent commercial scale. Pegylation, the attachment of polyethylene glycol to a molecule, can significantly improve the pharmacological and physicochemical properties of peptide and protein therapeutics and reduce side effects. This well-recognized delivery system for biologics can enhance protein stability, bioavailability and solubility, overcoming common challenges in the development of these therapeutics. The new services will leverage EMD Millipore's broad range of functionalized PEG products of different molecular weight and activation chemistry, as well as buffers, solvents and excipients, unit operations employed during the pegylation process and subsequent purification including tangential and normal flow filtration and chromatography.

EMD Millipore Announces Three Additions to its MAS-100® Product Family

EMD Millipore announced three additions to its MAS-100® product family. The MAS-100 Iso MH® and MAS-100 Iso NT® systems were developed for use in isolators and enable sampling at critical control points. The distinguishing feature of the MAS-100 Iso MH® system is its four sampling heads, which allow for increased monitoring capacity compared to single-head systems. The compact and easy-to-handle design of the MAS-100 VF® air sampler makes it well-suited for use in controlled environments. The MAS-100 Iso NT® system for monitoring air in isolators was developed according to GAMP 4 and ISO® 14698 standards. The fully validated air sampler contains an innovative double valve which integrates the sampling head into the decontamination process of the isolator. For added safety, electronic and moving parts remain outside the critical zone and an internal pump with flow control enables automatic disinfection of the sampling head and the aspiration tube. The MAS-100 Iso MH® air sampler offers all the benefits of the MAS-100 Iso NT® and allows installation of up to four sampling heads at all critical control points. Multiple heads from one pump provide increased capacity, easier installation and lower cost than four equivalent single-head systems. Additionally, the system extends up to 10 meters in tube length, which facilitates use in larger isolators. The system was developed according to GAMP 5 and ISO® 14698 standards. The MAS-100 VF® active air sampler was validated and developed for air monitoring in controlled environments. The system's compact design allows for ease of operation, and its added handle can be mounted on a tripod to test different angles for fixed applications. Electronic speed control ensures a consistent and accurate flow rate, and a touch-slide control menu enables simple menu navigation. The system programs sample volumes from 1 to 1,000 liters with five presets to assure reproducible results. The MAS-100® family includes systems for testing air and compressed gases in cleanrooms, aseptic production areas, isolators, and other controlled environments. MAS-100® microbial air samplers comply with the guidelines as specified in the new ISO® 14698 part 1 and part 2 standards.

EMD Millipore Expands Provantage Biodevelopment Services with Addition of Provantage Clone Generation Service

EMD Millipore announced expansion of its Provantage Biodevelopment Services to include a Clone Generation Service. With this addition, the company now provides a full range of services for optimizing yield, productivity, consistency and efficiency of clinical scale drug products. The new Clone Generation Service includes expression of recombinant proteins such as hormones, growth factors and mono- and bi-specific monoclonal antibodies. Customers can choose from DG44 and CHO-S cell lines, both of which are widely used for reliable and high-yield production of biologics. Availability of two cell lines offers greater flexibility to meet both the technical requirements and business objectives of customers. While the DG44 cell line offers freedom for process development, the CHO-S line can be more cost effective. Every clone generation is fully documented to ensure traceability from the source and demonstrate that the cell is clonal, making the cells usable for clinical production, IND submission and acceptance. Clone generation includes DNA synthesis of the sequence encoding the biologic, cloning of the sequence in a vector, transfection, and preparation of stable pools of producing cells, amplification of the expression cassette and subcloning of high-producing cells. The final deliverable is a pre-master cell bank of high-producing clones and a cell line generation report.

Similar Private Companies By Industry

Company Name Region
CyVek, Inc. United States
Finesse Solutions, Inc. United States
Regenerative Medical Solutions, Inc. United States
FujiFilm Diosynth Biotechnology Texas LLC United States
MolecularMD Corp. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
May 21, 2015
Singulex, Inc., Singulex Life Science Research Business
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EMD Millipore Corporation, please visit www.emdmillipore.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.